# A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

> **NCT03009981** · PHASE3 · COMPLETED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 504 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Apalutamide
- **DRUG:** LHRH Analogue
- **DRUG:** Abiraterone Acetate
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT03009981
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-06
- **Primary completion:** 2025-06-25
- **Final completion:** 2025-06-25
- **Target enrollment:** 504 (ACTUAL)
- **Last updated:** 2025-12-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03009981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03009981, "A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03009981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*